Literature DB >> 15083354

Dialogues on complex analgesic strategies for difficult pain syndromes.

Sebastiano Mercadante1, Patrizia Villari, Patrizia Ferrera.   

Abstract

Although the use of oral analgesics for the control of cancer pain has been demonstrated to be successful in most patients, some patients will fail to respond to pharmacological therapy or will suffer unacceptable adverse effects. Experience is accumulating that when adverse effects prevail with oral opioid administration, the analgesic response may be improved by changing the drug and/or the route of administration. Switching to an alternative opioid may further improve the balance between analgesia and adverse effects. Despite optimal systemic opioid treatment, in some complicated circumstances it is necessary to find different solutions, including the neuraxial administration of multiple drugs with different characteristics, which are difficult to manage. Three case reports illustrate how complex could be the analgesic approach using multiple analgesic regimens and different routes of administration to effectively manage complex pain syndromes commonly defined as unresponsive.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15083354     DOI: 10.1007/s00520-003-0575-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  16 in total

1.  Gabapentin for opiod-related myoclonus in cancer patients.

Authors:  S Mercadante; P Villari; F Fulfaro
Journal:  Support Care Cancer       Date:  2001-05       Impact factor: 3.603

2.  Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home.

Authors:  S Mercadante
Journal:  Cancer       Date:  1999-04-15       Impact factor: 6.860

3.  Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain.

Authors:  C Y Yang; C S Wong; J Y Chang; S T Ho
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

Review 4.  Opioid rotation for cancer pain: rationale and clinical aspects.

Authors:  S Mercadante
Journal:  Cancer       Date:  1999-11-01       Impact factor: 6.860

5.  Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain.

Authors:  A Caraceni; E Zecca; C Martini; F De Conno
Journal:  J Pain Symptom Manage       Date:  1999-06       Impact factor: 3.612

6.  Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report.

Authors:  M Stotz; H P Oehen; H Gerber
Journal:  J Pain Symptom Manage       Date:  1999-09       Impact factor: 3.612

7.  Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group.

Authors:  James C Eisenach; Stuart DuPen; Michel Dubois; Rafael Miguel; Douglas Allin
Journal:  Pain       Date:  1995-06       Impact factor: 6.961

Review 8.  Ketamine in cancer pain: an update.

Authors:  S Mercadante
Journal:  Palliat Med       Date:  1996-07       Impact factor: 4.762

9.  Histopathology after repeated intrathecal injections of preservative-free ketamine in the rabbit: a light and electron microscopic examination.

Authors:  F M Borgbjerg; B A Svensson; C Frigast; T Gordh
Journal:  Anesth Analg       Date:  1994-07       Impact factor: 5.108

10.  Reduction of nausea and vomiting from epidural opioids by adding droperidol to the infusate in home-bound patients.

Authors:  J A Aldrete
Journal:  J Pain Symptom Manage       Date:  1995-10       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.